201 related articles for article (PubMed ID: 18781096)
21. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
22. Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P.
Goode T; O'Connor T; Hopkins A; Moriarty D; O'Sullivan GC; Collins JK; O'Donoghue D; Baird AW; O'Connell J; Shanahan F
J Cell Physiol; 2003 Oct; 197(1):30-41. PubMed ID: 12942538
[TBL] [Abstract][Full Text] [Related]
23. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Mayordomo C; García-Recio S; Ametller E; Fernández-Nogueira P; Pastor-Arroyo EM; Vinyals L; Casas I; Gascón P; Almendro V
J Cell Physiol; 2012 Apr; 227(4):1358-66. PubMed ID: 21604273
[TBL] [Abstract][Full Text] [Related]
24. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
25. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
[TBL] [Abstract][Full Text] [Related]
26. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
27. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz M; Coveñas R
Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
[TBL] [Abstract][Full Text] [Related]
29. NK-1 as a melanoma target.
Muñoz M; Bernabeu-Wittel J; Coveñas R
Expert Opin Ther Targets; 2011 Jul; 15(7):889-97. PubMed ID: 21592000
[TBL] [Abstract][Full Text] [Related]
30. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
32. Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor.
Hamke M; Herpfer I; Lieb K; Wandelt C; Fiebich BL
Brain Res; 2006 Aug; 1102(1):135-44. PubMed ID: 16806114
[TBL] [Abstract][Full Text] [Related]
33. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration.
Dong J; Feng F; Xu G; Zhang H; Hong L; Yang J
Gene; 2015 Apr; 560(2):205-10. PubMed ID: 25659767
[TBL] [Abstract][Full Text] [Related]
34. Role for NK(1) and NK(2) receptors in the motor activity in mouse colon.
Mulè F; Amato A; Serio R
Eur J Pharmacol; 2007 Sep; 570(1-3):196-202. PubMed ID: 17597603
[TBL] [Abstract][Full Text] [Related]
35. Neonatal capsaicin treatment affects rat thymocyte proliferation and cell death by modulating substance P and neurokinin-1 receptor expression.
Santoni G; Amantini C; Lucciarini R; Perfumi M; Pompei P; Piccoli M
Neuroimmunomodulation; 2004; 11(3):160-72. PubMed ID: 15067207
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion.
Uzgare RP; Sheets TP; Johnston DS
Anticancer Res; 2013 May; 33(5):1989-2000. PubMed ID: 23645748
[TBL] [Abstract][Full Text] [Related]
37. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
38. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
39. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
Brown LF; Berse B; Jackman RW; Tognazzi K; Manseau EJ; Senger DR; Dvorak HF
Cancer Res; 1993 Oct; 53(19):4727-35. PubMed ID: 8402650
[TBL] [Abstract][Full Text] [Related]
40. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
